Table 1: Summary of nonengraftment cellular therapy results.

AuthorNumber of patientsConditioning regimenNumber of CD3 cells infusedResponse rate (CR/PR)

Colvin et al. [16]19 patients (AML/NHL only)100 cGy TBI1 × 106–2 × 108/kg37% (26%/11%)

Guo et al. [17]30 patients (AML)Mitoxantrone 8–10 mg/m2 (3 days) and cytarabine 150 mg/m2 (7 days)0.5–2.6 × 108/kg80% (80%/NR)

*O’Donnell et al. [18]4 patients (ALL, MDS)Fludarabine 30 mg/m2, 200 cGy TBI, Post transplant ± Pretransplant cyclophosphamide2.6–3.8 × 107/kg75% (75%/0%)

*Dey et al. [19]22 patients (NHL, HL, Multiple Myeloma)Cyclophosphamide 50 mg/kg (3-4 days), ATG 15–30 mg/kg (3-4 days), and anti-CD 2 monoclonal antibody1 × 107–2.98 × 108/kg41% (18%/22%)

*Only patients who did not engraft in this study are included in the results. AML= acute myeloid leukemia, NHL= non-Hodgkins lymphoma, MDS= myelodysplastic syndrome, ALL= acute lymphocytic leukemia, HL= Hodgkins lymphoma.